This past week I was thinking about the time I spent in Nepal with Coca- Cola to see the devastation after the earthquake and the global brand’s response to it. The April 2015 4.5 magnitude earthquake upended lives and left cities in rubble. I saw much of it during our travels through Kathmandu and its surrounding towns.
NGOs worked with their partners in the field to provide basic necessities for families, especially women and girls. And, Coca-Cola helped fund programs to empower women’s lives. One such programs I saw was Coca- Cola’s 5×20 program, a global initiative to empower five million women in its supply chain by 2020. Bottlers Nepal Limited committed to empowering 10,000 women in and around Kathmandu to help reach that milestone.
The 5×20 program had a global goal of empowering five million women by 2020. I recently went to see if that goal had been met last year. I was pleased that it had. In fact, Coca-Cola and its partners had helped six million women in 100 different countries reach economic empowerment.
I was happy to see the 5×20 economic empowerment program up close and am happy for the women who now have their own businesses to lean on.
When I was in Zambia I saw ways in which nurses treat cervical cancer in low resource settings. Women who do not benefit from the HPV vaccine and still develop cervical cancer are often subject to visual inspection of the cancer typically with a digital camera followed by cryotherapy to freeze the diseased part of the cervix. Some researchers question whether this approach to cervical cancer treatment is effective in low-and-middle income countries. Globally, the cervical cancer burden falls disproportionately upon women in low and middle-income countries. In fact, approximately 90% of deaths from cervical cancer occur in these countries like Bolivia, Guinea, and Swaziland. Rates are highest in Central America, sub-Saharan Africa, and Melanesia.
As I have written many times before postpartum hemorrhage (PPH) or excessive uterine bleeding after childbirth is the leading cause of maternal mortality in low-and-middle income countries. The recommended drug to prevent PPH according to the World Health Organization (WHO) is oxytocin. When administered in its recommended dose it causes little to no side effects. Oxytocin, the WHO’s current gold standard therapy, however, must be refrigerated and administered by skilled health workers posing two obstacles to its wider use in low resource, tropical settings.
Some countries have approved misoprostol, an oral drug, to prevent PPH, but there are several concerns that its use can be misappropriated for abortions instead of used solely for PPH. The World Health Organization has listed misoprostol as an alternative to oxytocin if it is not available.
Now, another PPH preventative drug, carbetocin, has been added to the latest updated 2019 WHO Essential Medicines List. The announcement was made last week. Unlike oxytocin, even at high temperatures carbetocin remains effective. The recommendation is that carbetocin can be used when oxytocin is not available or if its quality is uncertain. Additionally, the cost must be comparable to oxytocin.
Every day 800 women die during childbirth or from pregnancy complications. This startling statistic represents women who not only live in sub-Saharan Africa where most maternal deaths occur but also throughout the world.
In order to reduce the number of maternal deaths in low- and middle-income countries across the globe design teams, social entrepreneurs, innovators, and NGOs are creating innovative ways in which to save more mothers’ lives through inexpensive interventions that are conducive to low resource settings.
In many hospitals and health clinics, for example, power can go out at any moment requiring alternatives that allow health workers workarounds to the perpetual problem of power outages. In these settings, women can also experience life-threatening postpartum hemorrhage that requires immediate attention with interventions that stop bleeding. Additionally, some women do not have the money to afford the items needed during childbirth and innovators are solving those problems as well.
While maternal deaths have fallen 50 percent since 1990, in some countries the maternal mortality rate remains stagnant. Only half of expecting mothers in developing countries receive the health care they need to deliver healthy babies and to survive childbirth.
Below are five innovative interventions that are used in countries where maternal mortality is high in order to make a positive impact on saving mothers’ lives.
Jhpiego:(Updated, May 11, 2017) While Jhpiego developed a “testing pen” to catch and diagnose eclampsia in its earliest stages the project did not move forward after rigorous testing.
Safe Surgeries: Jhpiego has partnered with the GE Foundation, funder for the Safe Surgery 2020 Initiative, to ensure mothers have access to safe, affordable, life-saving caesarean sections in Ethiopia. With the help and input of Ethiopia’s Ministry of Health, Safe Surgery 2020 provides training, leadership skills, and updated procedures for safe surgeries at partner institutions in Ethiopia through implementing partner Jhpiego. The results have seen improved patient care and recovery, fewer surgery backlogs, reduced infections, and a holistic approach to safer surgeries.
PATH: PATH created an antishock garment that controls postpartum bleeding by applying pressure to the lower body and forcing blood upwards and prevents hemorrhage. Postpartum hemorrhage is the number one cause of maternal deaths.
PATH: PATH also developed a balloon tamponade to stop uterine bleeding early. While there are other balloon tamponades in the market, they are expensive and inaccessible, especially in the developing world.
But Trump wants to go even further than his GOP predecessors by slashing spending on global health efforts funded through the United States Agency for International Development (USAID). Deeper family planning retrenchment would, however, put millions of lives at risk.